Jonathan Chou

[Carissa Chu @CChuMD]

@jonchou05 delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder cancer. @UCSFCancer

#AACR26

The takeaways:

[Gunsagar Gulati @gungulati]

10/ APEX linked luminal programs to favorable outcomes and EMT signatures to poor outcomes. In enfortumab vedotin–treated bladder cancer, 58% of patients with high APEX-predicted NECTIN4 responded, compared to 0% with low NECTIN4.

Even after adjusting for tumor fraction, copy number, and clinical covariates, APEX-derived NECTIN4 remained independently associated with improved survival. Our preliminary data suggests that plasma-inferred NECTIN4 may outperform tissue NECTIN4 IHC in this task.

[Jonathan Chou @jonchou05]

Thanks to @UCSFCancer for covering our study which showed that a PPARg agonist rosiglitazone (an old diabetes drug) can modulate NECTIN4 & enhance activity of a new CAR T in #bladdercancer @CChuMD @koshkin85 @DrTFriedlander @SimaPorten @UCSFUrology https://t.co/edmCM1kk26

[Jonathan Chou @jonchou05]

@BladderCancerUS @NatureComms Huge thanks to @BladderCancerUS and @BCAN_Research for the YIA+support, amazing med student Kevin Chang & awesome mentors+collaborators @CChuMD @koshkin85 @corynnkasap @felixfengmd @apwiita @DrTFriedlander @SimaPorten @DSolit @DrRosenbergMSK @jklee_lab @UCSFUrology @UCSFCancer

[Bladder Cancer Advocacy Network @BladderCancerUS]

Research funded in part by BCAN with @jonchou05 in @NatureComms : Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Click here to read the article: https://t.co/9HuEN2syB6

[Bladder Cancer Advocacy Network @BladderCancerUS]

In @naturecomms: Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Click here to read the article: https://t.co/w9QE006asN

[Carissa Chu @CChuMD]

UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology
@SimaPorten @jonchou05 @koshkin85 @SamWashUro

[Nature Cancer @NatureCancer]

📢Check out this Article NOW ONLINE! @NatureCancer

'#Transcription and #DNAreplication collisions lead to large tandem duplications and expose targetable #therapeutic vulnerabilities in #cancer'

✏️By Jonathan Chou, Lixing Yang and colleagues

📎https://t.co/MyQVvgPWsq

[UChicagoCancerCenter @UCCancerCenter]

🔥 Hot off the press: Lixing Yang, PhD, and collaborators at @UCSF have published a ground breaking work in @NatureCancer, demonstrating how unrepaired collision of DNA replication and transcription can drive aggressive cancers. @UChicagoCCB @jonchou05
https://t.co/YLKqGCat5I

[UChicagoCancerCenter @UCCancerCenter]

📕 New publication alert: Lixing Yang, PhD and his collaborators at @UCSF published an exciting work demonstrating new approaches to correct the errors generated by the collision of DNA replication and transcription. @jonchou05 @NatureCancer @UChicagoCCB
https://t.co/Gg39yK3M5K

[Jonathan Chou @jonchou05]

@UCCancerCenter @UCSF @NatureCancer @UChicagoCCB Excited to share our work on TRCs, tandem dups, CDK12 and targeting strategies! Amazing to work w/ the incredible Yang Lab @UCCancerCenter @UChicago and thanks to our team at @UCSFCancer @UCSFUrology including mentors @felixfengmd @Ashworth_SF and @PCF_Science for the support!

[Prostate Cell News @ProstateCell]

In prostate cancer, sensitivity to poly ADP-ribose polymerase inhibitors is dependent on the specific type and zygosity of the CDK12 mutation, reports Dr. Jonathan Chou's team at @UCSF.

https://t.co/qRdFVgfLZ9

[Jonathan Chou @jonchou05]

@PGrivasMDPhD @fredhutch @HsiehLab @li_haolong @DrOmarMian @JLWrightMD @koshkin85 @GavinHa @DrTFriedlander @BladderCancerUS @Uromigos @JoshMeeks @TiansterZhang @jklee_lab @FaltasLab Thank you Petros, Andrew, Haolong and Michael for the invitation to visit and speak @fredhutch, and for taking me out for an amazing dinner! Great to meet old and make new friends!! @UCSFCancer

[Petros Grivas @PGrivasMDPhD]

Thanks @jonchou05 for visiting @fredhutch fantastic talk & dinner!
@HsiehLab @li_haolong @DrOmarMian @JLWrightMD @koshkin85 @GavinHa @DrTFriedlander @BladderCancerUS @Uromigos @JoshMeeks @TiansterZhang @jklee_lab @FaltasLab
Great opportunities for collaboration & translation!

[Terry Friedlander @DrTFriedlander]

Awesome #BCANTT24 this year. Great representation from #UCSF!

[bioRxiv Cancer Bio @biorxiv_cancer]

Histologic variants in bladder cancer harbor aggressive molecular features including TM4SF1 expression and a CA125+ cell state https://t.co/wBicWEkw1q #biorxiv_cancer

[Markus Eckstein @Markuseckstein3]

We are happy to share our new study published today @JCO_ASCO (👉 https://t.co/hS14mj8xPx) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered the role of NECTIN4 amplifications in enhancing the efficacy of Enfortumab Vedotin (EV), a cutting-edge treatment for metastatic urothelial cancer (mUC).
With NECTIN4 amplifications positioned as a potential genomic marker to predict responses to EV in mUC patients, let's explore how these findings could translated to other cancer entities as well!

Summary 👉 in posts below!

Link to paper: https://t.co/hS14mj8xPx

@AmerUrological @Uroweb @ASCO @PathSoc #Uropathology #urothelial #cancer #MedicalInnovation
@NEJM @JAMANetwork @JAMA_current @OncoAlert @onkowissen @imedverse @Histo_Journal @niklas_kluemper #pathtwitter @HolzelMichael @IEO_HolzelLab @brookmans76 @PGrivasMDPhD @DrYukselUrun @shilpaonc @drenriquegrande @amerseburger @JoshMeeks @roghmann @IvanyiPhilipp @GNiegisch @ViktorGruenwald @KuppeChristoph @AlbertoNakauma @OncoBellmunt @tompowles1 @montypal @DrChoueiri @neerajaiims @PTarantinoMD @sonpavde @DrRosenbergMSK @Dr_Aggen @koshkin85 @jonchou05 @EKFStiftung @dfg @UniFAU

[Niklas Klümper @niklas_kluemper]

@scserendipity1 @JCO_ASCO @PTarantinoMD @ASCO @urotoday @OncoAlert @imedverse @Markuseckstein3 Thanks @scserendipity1 We and others (https://t.co/S9WIFrv8vF) believe yes: Membranous NECTIN4 expression is correlated to EV response. Further, app. 40% of oUC metastatic samples are lacking membranous NECTIN4 https://t.co/JmfOUNobel

[OncoDaily @oncodaily]

Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma - @PTarantinoMD
@niklas_kluemper

#BreastCancer #DanaFarberCancerInstitute #GU24 #HER2 #ExperimentalOncology #LungCancer

https://t.co/C4pVDLIgTH

[Niklas Klümper @niklas_kluemper]

Great overview on UC pathology @Markuseckstein3 🔥 important to keep these pathways of UC carcinogenesis in mind for ADC targets as well, as NECTIN4 is overexpressed in luminal tumors as nicely demonstrated by @jonchou05 https://t.co/y9gkotHqZY in @CCR_AACR @urotoday @OncoAlert